hengrui glp-1 New GLP-1R agonists disclosed in patent Hengrui and Kailera report best-in-class

Rare but severe complications include pancreatitis and gallbladder problems

were stripping out the metabolic "gunk." The "Anabolic Incretin" Era: We are moving from "weight loss drugs" to Body Composition Modulators

Call +971 56 403 3528 or WhatsApp to book IV Drip Therapy for Dubai's Climate Dubai's extreme summer heat (regularly exceeding 45C from June to September) creates unique hydration and nutrient demands

A phase 2 study of novel therapy Y for diabetic nephropathy

Afamelanotide (Scenesse, Clinuvel Pharmaceuticals) is a linear MC1R selective tridecapeptide, approved by the FDA on October 8, 2019, and by the EMA on December 22, 2014, exclusively for the treatment of erythropoietic protoporphyria (EPP) in adults

This all-encompassing approach greatly impacts diabetes management and weight loss